摘要
Dear Editor,Anaplastic lymphoma kinase(ALK)rearrangement is a key driver gene in non-small cell lung cancer(NSCLC),and the effectiveness of targeted therapies directed at ALK fusion has been confirmed.1 However,the activity of ALK-tyrosine kinase inhibitors(ALK-TKIs)against rare ALK rearrangements is variable,with limited clinical evidence.Here,we reported the case of a novel kinase D interacting substrate 220(KIDINS220)-ALK fusion that showed favorable response to alectinib.
基金
supported by the National Natural Science Foundation of China(Grants No.81872489 and 82073369)
the Natural and Science Foundation of Sichuan Province(Grant No.2022NSFSC1412)。
